Table 1. Comparison of patient clinicopathological characteristics between the PIK3CA mutation and PIK3CA wild-type groups.

Characteristic	PIK3CA mutation status (%)		P
	Mutation (N=11)	Wild-type (N=39)
Age	52.73±14.157	53.72±11.546	0.388
Tumor size (cm)			0.096
≤2	6 (54.5)	18 (46.2)
2–5	3 (27.3)	20 (51.2)
>5	2 (18.2)	1 (2.6)
Tumor location			0.468
Left	7 (63.6)	20 (51.2)
Right	4 (36.4)	19 (48.8)
No. of positive axillary nodes			0.712
0	7 (63.6)	27 (69.2)
≤4	1 (9.1)	6 (15.4)
4–9	2 (18.2)	5 (12.8)
>10	1 (9.1)	1 (2.6)
Histological grade			0.594
SBR II	3 (27.3)	14 (35.9)
SBR III	8 (72.7)	25 (64.1)
TNM stage			0.447
I	6 (54.5)	13 (33.3)
II	2 (18.2)	17 (43.6)
III	2 (18.2)	5 (12.8)
IV	1 (9.1)	4 (10.3)
Relapse			0.880
No	10 (90.9)	36 (92.3)
Yes	1 (9.1)	3 (7.7)
Metastasis			0.909
No	10 (90.9)	35 (89.7)
Yes	1 (9.1)	4 (10.3)
Survival status			0.880
Live	10 (90.9)	36 (92.3)
Dead	1 (9.1)	3 (7.7)
Family cancer history			0.412
Yes	9 (81.8)	27 (69.2)
No	2 (18.2)	12 (30.8)
P53 status			0.248
Negative	3 (27.3)	5 (12.8)
Positive	8 (72.7)	34 (81.2)
Ki67			0.329
≤14%	1 (9.1)	1 (2.6)
>14%	10 (90.9)	38 (97.4)